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M6A associated TSUC7 inhibition
contributed to Erlotinib resistance in lung
adenocarcinoma through a notch signaling
activation dependent way
Kai Li1†, Zi‑Yang Peng1†, Shan Gao1†, Qing‑Shi Wang1, Rui Wang1, Xiang Li1,2, Guo‑Dong Xiao3, Jing Zhang1,
Hong Ren1, Shou‑Ching Tang4* and Xin Sun1*

Abstract
Background: The small tyrosine kinase inhibitors (TKIs) subversively altered the lung cancer treatments, but patients
will inevitably face the therapy resistance and disease recurrence. We aim to explore the potential roles of non-coding
RNAs in sensitizing the TKIs effects. Methods: Multiple cellular and molecular detections were applied to confirm the
mechanistic regulations and intracellular connections.
Results: We explored the specific gene features of candidates in association with resistance, and found that m6A
controlled the stemness of EMT features through METTL3 and YTHDF2. The miR-146a/Notch signaling was sustained
highly activated in a m6A dependent manner, and the m6A regulator of YTHDF2 suppressed TUSC7, both of which
contributed to the resistant features. Functionally, the sponge type of TUSC7 regulation of miR-146a inhibited Notch
signaling functions, and affected the cancer progression and stem cells’ renewal in Erlotinib resistant PC9 cells (PC9ER)
and Erlotinib resistant HCC827 cells (HCC827ER) cells. The Notch signaling functions manipulated the cMYC and DICER
inner cytoplasm, and the absence of either cMYC or DICER1 lead to TUSC7 and miR-146a decreasing respectively,
formed the closed circle to maintain the balance.
Conclusion: PC9ER and HCC827ER cells harbored much more stem-like cells, and the resistance could be reversed
by Notch signaling inactivation. The intrinsic miR-146 and TUSC7 levels are monitored by m6A effectors, the alterna‑
tion of either miR-146 or TUSC7 expression could lead to the circling loop to sustain the new homeostasis. Further in
clinics, the combined delivery of TKIs and Notch specific inhibitory non-coding RNAs will pave the way for yielding the
susceptibility to targeted therapy in lung cancer.
Keywords: Tyrosine kinase inhibitors, Notch signaling, Cancer stem cells, Therapy resistance, N6-methyladenosine
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Background
Lung cancer is the most dangerous cancer type worldwide, topping the cancer related mortality [1]. The lung
cancer incidence tends to be stable, and even decreased
slightly in western world [1, 2], but situations on cancer prevention were severe in developing China [3–5].
Exploring more sensitive screening strategy, improving
the radical operation methods, or developing more
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effective adjuvant therapeutic agents was so urgent than
ever [6, 7]. Lung adenocarcinoma consists of lots of therapy targets, and the EGFR Tyrosin Kinase related Inhibitors (TKIs) have been widely and effectively applied in
clinical treatments for a decade, shortening the suffering
process [8, 9]. However, inevitably, the targeted therapies
must face the recurrence, and receive the second or third
line of chemo-radiotherapy [10–12], and to identify more
novel and effective therapeutic molecules and agents will
be helpful and promising.
Traditional non-coding genes were always referred to
the miRNAs when researching the post-translational regulations, and the lncRNAs (long non-coding RNAs) and
circRNAs (circular RNAs) were later revealed for supplementing the affection of RNA family of non-coding
members [13–17]. Individually, they could act as crucial
modulator toward to certain downstream genes in many
ways [18, 19]. The N-6-methyladenosine (m6A) regulation of RNAs attracted lots attention due to its specific
and strong modification ability of epigenetic functions
[20–22]. The m6A controller of writers, readers, and
erasers could modulate the mRNA stability and translation, to mediate downstream effects [23, 24]. However,
the roles of m6A in controlling the non-coding RNAs
biogenesis were still not clear. To further identify the
candidates to improve the TKIs treatments sensitization,
we tentatively explored the supporting role of TUSC7 in
cancer suppression, trying to establish the m6A correlated lncRNA functions in modulating the TKIs therapies
resistance.

Quantitative real‑time PCR and western blot

Materials and methods

Sphere formation assay

Cell lines and cell culture

The human lung adenocarcinoma cells lines (PC9 and
HCC827), and human embryonic cell line (HEK-293 T)
were purchased from ATCC (American Type Culture
Collection, VA, USA) or the Cell Bank of the Chinese
Academy of Sciences (Shanghai, China). The Erlotinibresistant cell lines (PC9/ER and HCC827/ER) were established by chronic exposure to increasing concentrations
of drugs. The ectopic expression of TUSC or miR-146
in cells were constructed and restored as pervious study
elucidated [25]. All cell lines were cultured in DMEM
medium supplemented with 10% FBS (Gibco), 1% penicillin and 1% streptomycin, and incubated at 37 °C in a
humidified atmosphere with 5% C
 O2.
Materials and agents

The Notch inhibitors were chosen as FLI-06 (inhibitor-1,
ab120633, Abcam), and γ-Secretase inhibitor (inhibitor-2, ab146170, Abcam). Erlotinib was purchased from
Sigma-Aldrich (SML156-50MG, Merck KGaA, Darmstadt, Germany).

Total RNA was extracted from cells using Trizol, according to the manufacturer’s protocol, and reverse-transcribed into cDNA by using SYBR RT-PCR kit (Takara,
JAPAN). Real-time quantitative PCR (RT-qPCR) was
performed with SYBR Premix ExTaqTM II Kit (Takara,
JAPAN). The sequences of the primers for PCR were synthesized by Sangon Company (Shanghai, China) and were
listed in Supplemental Materials and Methods. The relative expression of mRNA and miRNA were calculated by
using the formula:2-ΔΔCΤ. For western blot analysis, the
total protein from cell extracts was harvested using RIPA
buffer contained protease inhibitors. The protein extracts
were fractionated by 10% SDS-PAGE, transferred onto a
nitrocellulose membrane, and then incubated with primary antibodies at 4 °C overnights, followed by HRP-conjugated secondary antibody (1:5000, #7074, Cell Signaling
Technology) and visualized by using ECL Blotting Detection Reagents (Merck Millipore). The primary antibodies
were as follows: anti-Notch1 (1:500; Rabbit mAb, #3608,
Cell Signaling Technology), anti-Notch2 (1:1000, ab8926,
Abcam), anti-NCSTN (1:1000, ab189125, Abcam), antiVinculin (1:8000, #4650, Cell Signaling Technology),
anti-NUMB (1:1500, #2761, Cell Signaling Technology),
anti-EGFR (1:2000, #4267, Cell Signaling Technology),
anti-DICER1 (1:500, #5362, Cell Signaling Technology),
anti-CMYC (1:1500, (9E10): sc-40, Santa Cruz), antiSnail (1:1000, ab31787, Abcam), anti-METTL3 (1:2000,
ab240595, Abcam), anti-YTHDF2 (1:1000, EPR20318,
ab220163, Abcam).

Single-cell suspensions (1000 cells per well) of different groups were plated on six-well ultralow attachment
plates (Corning Incorporated) in serum-free DMEM/F12
Medium supplemented with 20 ng/mL EGF (Invitrogen,
Carlsbad, CA), b-FGF (Invitrogen, Carlsbad, CA) and
4 μg/mL insulin (Sigma-Aldrich, St. Louis, MO). After
1 week culture, the spheres of>50 μm was quantified by
using an inverted microscope.
Dual luciferase report assay

The putative sequences or mutant sequences of miR146a target sites for TUSC7–3’UTR was synthesized
and cloned into the pGL3 reporter vector (Promega).
These constructed reporters were named pGL3-TUSC7WT, pGL3-TUSC7-MUT. For luciferase assay, the cells
were seeded onto 24-well plates and co-transfected with
200 ng of pGL3-TUSC7/EGFR-WT or pGL3-TUSC7/
EGFR -MUT, 20 ng of pRL-TK plasmid as normalization control, together with miR-146a-5p mimic or miR146a-5p control (GenePharma, Shanghai, China). After
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48 h of transfection, Luciferase assays were performed by
using the Dual Luciferase Reporter Assay System (Promega, WI, USA).
ALDEFLUOR assay and fluorescence‑activated cell sorting
(FACS)

Aldehyde dehydrogenase (ALDH) enzyme activity in
lung cells was determined by ALDEFLUOR assay kit
(Stem Cell Technologies, Grenoble, France) according to
the manufacturer’s instructions. Briefly, 1 × 106/ml cells
mixed with Aldefluor® assay buffer containing 1.5μΜ
bodipy-aminoacetaldehyde (BAAA, an ALDH substrate).
Then, the cell/substrate mixture was incubated for 1 h
at 37 °C. Diethylaminobenzaldehyde (DEAB), a specific
ALDH1 enzyme inhibitor, was used as negative control.
The ALDH + population was detected in the green fluorescence channel (520–540 nm) of FACSAria (Becton
Dickinson). Stained cells analyzed and sorted by utilizing FACSDiva (BD Biosciences) and Flow-Jo software
(Treestar, Ashland, OR). Nonviable cells were excluded
using 1 μg propidium iodide (PI; Sigma Aldrich, Vienna,
Austria).
RNA‑immunoprecipitation

The cells (5 × 106)/ml were harvested and washed twice
with ice-cold 1 × PBS buffer. Collected cell pellet was
lysed for 15 min on ice by RIP buffer for 30 min, and
pretreated with a 1:10 dilution in NT2 buffer. The cell
lysate was further centrifuged at 15,000×g for 15 min
at 4 °C, followed by treated with magnetic beads conjugated to human anti-ATG3 antibody (1:50) or the control
IgG for 18 h at 4 °C and further washed twice with cold
NT2 Buffer. Magnetic beads subsequently mixed with
the diluted lysates (10 μl beads/ml lysate). The mixture
was re-suspended in 100 μl NT2 Buffer containing 30 μg
proteinase K to digest the protein. Co-purified RNA was
extracted by the TRIzol reagent and used in subsequent
qRT-PCR assay.
M6A methylation quantification assay

The m6A methylation status of cells detected using the
m6A RNA Methylation Quantification Kit (Epigentek,
Cat#P-9005-113) according to the manufacturer’s
instructions. In brief, 200 ng of total RNA was used as an
input respectively. Then RNA samples were captured and
detected by spectrophotometer (Bio Tek Instruments,
Inc. US) at 450 nm. The level of m6A methylation was
calculated according to the manufacturer’s instructions.
As for LC–MS/MS assay, mRNA was purified from
the total RNA using via oligo dT magnetic beads. Then
200 ng mRNAs were incubated with 0.5 U nuclease P1 in
reaction system at 42 °C for about 1 h. After that, mRNAs
were incubated with 3 μL of 1 M NH4HCO3 and 1 μL of
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1 U/μL alkaline phosphatase at 37 °C for 2 h. And mRNAs
were diluted and filtered. After which, a C18 column
were used to separate mRNAs [26–29]. Then mRNAs
were analyzed by an Agilent (6410 QQQ) triple-quadrupole LC mass spectrometer. Calibration curves were used
to calculate the Ratio of m6A to A.
Nude mouse xenograft model

A total of 21 4-week-old female BALB/cA-nu nude mice
were purchased from Beijing Huafukang Biosciences
(Beijing, China), then we maintained them in specific pathogen-free conditions. Control vector, TUSC7
knockout, FLI-06 treated H1975 cells (1*107) cells were
suspended in 100 μL of serum-free DMEM medium
(Hyclone, USA), mixed with matrix gel (Corning, USA),
and then were injected subcutaneously. The changes in
the tumor size were recorded every 3 or 5 days. We calculated the tumor volume using the following formula:
V = 1/2 × l × w2 (l is the longer axis, 2 is the shorter axis).
All mice were sacrificed 28 days after the injection of
cells. The dissected tumor samples were immersed in 4%
paraformaldehyde (BioSharp, China) and embedded in
paraffin.
Statistical analysis

Statistical analysis was carried out by using Graph
Pad Prism 6 and SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). All numerical data were expressed as
mean ± standard deviation (SD). Experiments were carried out with three or more replicates. Two or more
groups were assessed by using Student’s t test or ANOVA
individually. P < 0.05 was considered to be statistically
significant.

Results
Notch signaling activation in lung adenocarcinoma
pointed to poor survival expectance

The important members of Notch signaling [30, 31]
were screened for expression patterns with using PanCancer Atlas of TCGA data base. The total samples of
507 patients were collected, and the heat maps indicated
the universal overexpression of notch signaling participants (Fig. 1A-B), and EGFR was correlated with aberrant
Notch expression. Deep analysis from TCGA (Nat Genet
2016 data base) indicated the grouped enrichment of
Notch signaling factors (Fig. 1C), and the changing was
consistency in groups harboring most irregulated Notch
functions (Fig. 1D).
The overall survival (OS) and Disease/Progression-free
survival (DFS/PFS) data were acquired from TCGA data
at the CBIOPORTAL FOR CANCER GENOMIC (http://
www.cbioportal.org/) [32, 33]. Notch signaling activation
decreased the survival time (Fig. 1E), and patients tended
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to bear relapse or resistance in shorter follow-up periods
(Fig. 1F). The overall survival and first progression estimates were analyzed by applying Kaplan-Meier analysis (http://kmplot.com/analysis/) [34–36]. The highly
expressed TUSC7 indicated better progression-free
estimates in adenocarcinoma, comparing to the lower
expressed groups (Fig. 1G). The functional EGFR signaling could transcriptionally activate multiple downstream
pathways, and the positive relationship between miR146a and EGFR was found (Fig. 1H). MiR-146 also correlated with Notch signaling factors expressions (Fig. 1I-J).
Erlotinib resistant cells harboring notch signaling
activation and TUSC7 inhibition

Lung adenocarcinoma cell lines of PC9 and HCC827
were selected for their characteristics of specific EGFR
mutant status, and the signatures of PC9 and HCC827
cells referring to erlotinib treatment were shown in Figure S1. The concentration of 0.2 μM Erlotinib was chosen
as the function candidate, which decreased the Notch1
(Figure S2A) and Notch2 (Figure S2B) mRNA levels
in PC9 and HCC827 cells. The Erlotinib treatment also
increased the TUSC7 expression level significantly (Figure S2C), together with EGFR level slightly decreased
(Figure S2D). Blotting results showed that the Erlotinib
treatment decreased the Notch signaling factors in PC9
and HCC827 cells (Figure S2E).
We constructed Erlotinib resistant lung cancer cells
with advancing concentration gradient (Figure S3), and
the differentially expressed lncRNAs between Erlotinib
sensitive and resistant cells were primarily detected
by gene panel selection (Figure S2F). The differentially
expressed lncRNAs were pasted for GO analysis of functional identification (Figure S2G). The detailed information showed that TUSC7 of both PC9ER (Figure S2H)
and HCC827ER (Figure S2I) decreased greatly, and did
not react to Erlotinib treatment, comparing to the Erlotinib sensitive cells. Last but not least Erlotinib failed
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to inhibit the Notch signaling functions in PC9ER and
HCC827ER cells (Figure S2H-I).
Notch signaling inhibition was required for TUSC7
alleviating of the Erlotinib resistance

The stem-like cells were accused for treatment resistance, and to study the stem cells’ renewal ability in contributing to Erlotinib resistance, the ALDH1 phenotype
and spheres formation nature were applied. The Erlotinib resistant PC9ER and HCC827ER cells consisted
of more stem-like cells (Fig. 2A-B), and Erlotinib treatment failed to decrease the stem cells number (Fig. 2C).
Higher stem cells ratio indicated resistant status, and
resulted in group resistance. The Notch inhibitors were
chosen as FLI-06 (inhibitor-1, ab120633, Abcam), and
γ-Secretase inhibitor (inhibitor-2, ab146170, Abcam).
Both PC9 and HCC827 cells responded to Notch signaling inhibitors, with stem-like cells ratios decreasing
significantly (Fig. 2D-E). The lowered concentration of
Notch signaling inhibitors sensitized resistant cells to
Erlotinib treatment (Fig. 2F, Figure S4A-B), indicating
the synergistic effects of TKI agents and Notch signaling
inhibitors.
To study the TUSC7 functions, Lentiviral based
TUSC7 expression vesical was introduced into PC9ER
and HCC827ER cells. Erlotinib alone inhibited the Notch
signaling slightly, but TUSC7 effectively enhanced the
Erlotinib functions in PC9ER (Fig. 2G) and HCC827ER
cells (Fig. 2H), and stimulated the suppressive functions
of Erlotinib in both PC9ER (Figure S4C) and HCC827ER
cells (Figure S4D). Moreover, the addition of lowered
concentration of Notch signaling inhibitor strengthened
TUSC7 functions (Fig. 2G-H).
Next, we found that combined TUSC7 and Erlotinib
decreased the stem cells ratio greatly in both PC9ER
(Fig. 2I) and HCC827ER cells (Fig. 2J). The stem cells’
renewal suppression evaluation did not show significant differences between TUSC7 alone and the combination of TUSC7 and FLI-06 (Fig. 2K-L, Figure S4E-G).

(See figure on next page.)
Fig. 1 Aberrant Notch signaling activation in Lung adenocarcinoma. Notch signaling of NOTCH1, NOTCH2, NOTCH3, NOTCH4, DVL1, NUMB,
NCSTN, APH1A, SNW1, DTX2, DTX3, DTX1, NCOR2, CTBP2, CTBP1, HDAC1, HDAC2, CIR1, RBPJ, RBPJL, CREBBP, KRAS, MAPK1, MAPK1 were applied for
expression level detection, and a total of 507 lung adenocarcinoma samples with mutation and CNA data (TCGA, Pan-Cancer Atlas) were collected.
A Expression plots showed the key members of Notch signaling were amplified, together with EGFR overexpression, and KRAS mutations. B Heat
map results revealed the universal overexpression of Notch signaling participants, and the TUSC7 result was limited due to the mRNA expression
screening system restrictions. Specifically, expression level of TUSC7 showed the reverse consistency with the Notch signaling activation patterns.
The TCGA samples data with mutation and CAN from Pan-Lung Cancer (Nat Genet 2016) indicated the grouped enrichment of the Notch signaling
factors in Volcano Plots (C), and the changing frequency of each member was consistent with groups alternations (D). E-F The Overall survival
and Disease/Progression-free estimates with using Kaplan-Meier analysis showed that Notch signaling activation decreased the survival time, and
patients tended to bear relapse or resistance in shorter follow-up periods. G The relative higher level of TUSC7 indicated longer survival time of
all lung carcinoma patients significantly, comparting to the lower expressed groups. Sourced data of Star-Base (v3.0 Project) were collected and
analyzed, and the results were calculated with using RPM/Log manner, and a total of 512 lung adenocarcinoma samples were enrolled and applied
for analysis. H The positive relationship between expression level of miR-146a and level of EGFR was found in total of 512 lung adenocarcinoma
samples. Both Notch 1 (I) and Notch 2 (J) were positively correlated to miR-146a expression, pointing to the oncogenic functions of miR-146a
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Fig. 1 (See legend on previous page.)

The combined TUSC7 and Erlotinib decreased the
stem cells associated signatures, decreasing EMT
markers in PC9ER cells (Figure S5A) and HCC827ER
cells (Figure S5B).

TUSC7 sensitization of Erlotinib through miR‑146a/notch
signaling inhibition was dependent on NUMB restoration

To reveal the transduction mechanisms, bioinformatic
screening of the possible connections between TUSC7
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and its binding partners was conducted. We noticed
that miR-146a shared common sequences with the
untranslated regions of TUSC7 (Fig. 3A), and miR-146a
mimics decreased the Luc-activity of TUSC7 significantly (Fig. 3B) in 293 T cells, which was also confirmed
in PC9ER (Fig. 3C) cells and HCC827ER cells (Fig. 3D).
To testify the binding probabilities between TUSC7
and its downstream partner, biotin labeled sense and
anti-sense RNAs of TUSC7 were used for RNA pull
down detection, and the connection between TUSC7
and NUMB in resistant lung adenocarcinoma cells was
identified (Fig. 3E). Further, RNA immunoprecipitation
revealed that TUSC7 was enriched with NUMB expression in PC9ER cells (Fig. 3F, left) and HCC827ER cells
(Fig. 3F right). Informatic screening of the potential
miRNAs’ targets suggested that miR-146a may bind to
NUMB (Fig. 3G), and NUMB decreased greatly in cancer group (Fig. 3H). The alignment of miR-146a and the
3’UTR of NUMB was constructed through using the
enhanced green fluorescent protein (EGFP) reporter
assay. The wild-type 3’UTR sequence and the mutant
3’UTR sequence of NUMB were cloned downstream
from the EGFP-coding sequence respectively, to construct the reporter plasmid and the mutant vector. The
co-transfection of miR-146a mimics and the wide-type
reporter plasmid strongly reduced the EGFP intensity
(Fig. 3I, left), but not happened in mutant-type reporter
plasmid (Fig. 3I, right). On the contrary, TUSC7 did not
reduce the EGFP activity of the NUMB (Fig. 3J). MiR146a decreased the NUMB expression, which could be
rescued by TUSC7, and the TUSC7 inhibition (TUSC7in) also decreased the NUMB at the protein level
(Fig. 3K).
m6A in resistant cells contributed to TUSC7 inhibition
and miR‑146a overexpression

The pluripotency status of resistant PC9ER and
HCC827ER cells contributed to specific miR-146a and
TUSC7 patterns, and to characterize the roles of m6A
in therapy resistance, we investigated the variations
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of m6A levels, and identified that the m6A levels of
total RNAs from resistant cells were statistically more
abundant than sensitive original cells by using LC/MS
(Fig. 4A). To further characterize the roles of m6A in
generating the resistance, we used siRNAs to tentatively test the m6A related processers in controlling
of TUSC7 and miR-146a. METTL3 affected the miR146a level (Fig. 4B), and YTHDF2 affected TUSC7 level
(Fig. 4C),and results were all confirmed by using the
lentiviral based METTL3/YTHDF2 knock-down systems (Fig. 4D-E). Dysregulated METTL3 (Fig. 4F) and
YTHDF2 (Fig. 4G) affected the EMT and pluripotency
features through controlling m6A status. Moreover,
decreasing either METTL3 or YTHDF2 significantly
altered Snail and EMT factors expressions. m6A at
Snai1 mRNA was greatly increased in resistant cells [26,
37], and we found the METTL3 inhibition decreased
m6A at Snai1(Fig. 4H-I), which later failed to activate
the miR-146a promoter (Fig. 4J) [38]. In the other hand,
the m6A at TUSC7 level increased in resistant cells
(Fig. 4K), and the recognition of TUSC7 m6A peak by
YTHDF2 degraded TUSC7 [39, 40]. The Me-RIP (methylated RNA immunoprecipitation) assay confirmed that
the high abundance of m6A modification in cells with
YTHDF2 inhibition (Fig. 4L). All the results revealed
that m6A determined the expression levels of miR-146a
and TUSC7 in resistant cells, sustaining the balanced
status.
TUSC7 formed feedback loop with miR‑146/notch
signaling and lead the Erlotinib re‑sensitization

The unique m6A at different RNA sequences determined
intrinsic RNA expressions, cellular homeostasis may be
disturbed when manipulating certain lncRNA candidate.
CMYC was proved previously to promote the translation
of lncRNAs [41–43], and DICER1 was critical for miRNAs maturation [44–46]. Results showed that in PC9ER
and HCC827ER cells, Notch signaling inhibition lead to
cMYC promoter activity decreasing, and TUSC7 inhibition strongly increased the activity (Fig. 5A). Inhibition of

(See figure on next page.)
Fig. 2 Notch inhibition decreased the self-renewal ability of Erlotinib resistant cells and re-sensitized the resistant cells to Erlotinib. A The addition
of Erlotinib decreased the ALDH1A1 positive cells of PC9 and HCC827 cells significantly, but did not affect the ratios of Erlotinib resistant PC9ER and
HCC827ER cells. B The addition of Erlotinib decreased the spheres number of PC9 and HCC827 cells significantly, but did not affect the number
of Erlotinib resistant PC9ER and HCC827ER cells. C Representative images of ALDEFLUOR isolation were detailed exhibited. Two kinds of Notch
signaling inhibitors, FLI-06 (inhibitor-1), and γ-Secretase inhibitor (inhibitor-2) were used. 200 nM of inhibitor-1 (D) decreased the self-renewal ability
of multiple kinds of lung cancer cells, and 50 nM of inhibitor-2 (E) decreased the self-renewal ability of multiple kinds of lung cancer cells. F Notch
signaling inhibition decreased the stem cells’ ratio of the Erlotinib resistant cells significantly, and further, the much-lowered concentration of Notch
signaling inhibitor-1, the 20 nM of FLI-06 sensitized both PC9ER and HCC827ER cells to Erlotinib treatment greatly. Erlotinib alone inhibited the
Notch signaling slightly, and lowered concentration of FLI-06 mildly inhibited the Notch signaling, but effectively enhanced the Erlotinib functions
in PC9ER (Fig. 3G) and HCC827ER cells (Fig. 3H). Combined TUSC7 and Erlotinib decreased the stem cells ratio greatly in both PC9ER and HCC827ER
cells (Fig. 3I-J). K-L The stem cells’ renewal suppression evaluation did not show significant differences between TUSC7 alone and the combination
of TUSC7 and FLI-06
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Fig. 3 MiR-146a conducted NUMB degradation was blocked by TUSC7 in a sponge combination manner. A The predicated connection sites
between TUSC7 and its binding partners showed that miR-146a shared the common untranslated regions. B Recombined miR-146a mimics
decreased the Luc-activity of TUSC7 in 293 T cells. MiR-146a decreased the Luc-activity of TUSC7 in PC9ER cells (C) and HCC827ER cells (D).
E Blotting results referring to RNA pull-down test showed the connection between TUSC7 and NUMB in PC9ER and HCC827ER cells. F RNA
immunoprecipitation revealed that TUSC7 was enriched with NUMB expression in PC9ER cells (Left) and HCC827ER cells (Right), and the IgG was set
as the immunoprecipitation control, the MALAT1 was set as the primer control. G Informatic screening of the potential miRNAs’ targets suggested
that miR-146a may bind to NUMB. H The expression level of NUMB with 526 cancer and 59 normal samples in LUAD, and the expressions with 501
cancer and 49 normal samples in LUSC were evaluated, and NUMB decreased greatly in cancer group. I The co-transfection of miR-146a mimics and
the wide-type reporter plasmid strongly reduced the EGFP intensity, and miR-146a mimics reduced nearly 40% of the TUSC7 luciferase intensity,
but not happened in mutant-type reporter plasmid. J TUSC7 alone did not reduce the EGFP activity of NUMB. K MiR-146a decreased the NUMB
expression, which could be rescued by TUSC7, and the TUSC7 inhibition (TUSC7-in) also decreased the NUMB level
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TUSC7 increased miR-146a expression, and then stimulated the DICER1 activity (Fig. 5B).
The scheme image represented the cMYC promoter
detection modes (Fig. 5C), and the mutation blocked
the EGFR/Notch signaling feedback loop on lncRNA
transcription induction. Western blotting further confirmed that in PC9ER and HCC827ER cells, miR-146 and
TUSC7 acted the opposite way to promote the DICER1/
CCND1 expression (Fig. 5D). TUSC7 and miR-146a was
sustained by cMYC (Fig. 5E, left) and DICER1 (Fig. 5E,
right) respectively. The regulative signaling pathways
were drafted and illustrated for detailed exhibition
(Fig. 5F), the dysregulated TUSC7 and miR-146a formed
the feedback loop with their downstream effectors to sustain the new homeostasis.
In vivo study confirmed the effective inhibition of
TUSC7 exhibited on tumor growth, and the Notch signaling inactivation by using FLI-06 also suppressed the
in vivo tumor expansion (Fig. 5G), further proved its suppressive functions.

Conclusion
Lung cancer treatments have been refined greatly, with
constantly and novelly emerging components, and the
small molecular compounds improved the life quality
and expected response to therapies in patients carrying
sensitive EGFR mutants [47–49]. Surgery manners have
been evolved continuously with little operation wound
and duration, however, the improvement has brought
little progress on overall survival [50–52]. The 1st generation of small tyrosine kinase inhibitors subversively
altered the lung cancer treatments, and the “small step”
has made the “major progress”, increasing the PFS with
little suffering.
Reality is cruel. No matter how ideal results the TKIs
treatment has brought, patients with advanced lung cancer will inevitably face the therapy resistance and disease
recurrence [53–55]. To improve the TKIs sensitization
and to overcome resistance will be the headline goal in
the current emergency [56]. Many factors were thought
to be correlated with 1st generation of TKI functions’
achieving, and certain genes and compounds sensitized
the treatments by oncogenic signaling repression, but
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detailed mechanistic regulations have not been illustrated clearly ever [10, 57].
We have been focusing on noncoding RNAs related
cancer emergence, progression, stemness features and
therapy response for decades, and have revealed some
important factors that may contribute to [44, 45, 58]. Previously, we identified the miR-146 functions in lung adenocarcinoma with suppressive affections on stem cells’
renewal, and the tentative exploration of TKIs treatment
improvements will facilitate its practical application.
In this study, we identified the inhibitive roles of
TUSC7 in lung cancer progression, and after acquiring
the Erlotinib resistant cells, gene panel was used for massive assessing of the dysregulated non-coding RNAs. We
first explored the features of candidate genes in association with resistance, and the activated miR-146a/Notch
signaling was sustained in resistant stem cells in a m6A
dependent manner of and METTL3/Snail cascade. M6A
related YTHDF2 mediation of suppressed TUSC7 also
contributed to resistant features. Functionally, m6A controlled the stemness of EMT features through METTL3
and YTHDF2 in resistant PC9ER and HCC827ER cells.
In detail, TUSC7 sensitized the Erlotinib effects, and
decreased the stem cells ratio through Notch signaling
inhibition. Bench study showed that, TUSC7 sponged
to miR-146 and then released NUMB to control Notch
signaling, the latter of which was critical for maintaining cancer stem cells (CSCs) pool. DICER1 and cMYC
activity was critical for sustaining the non-coding RNAs
maturation [41, 43, 46, 59, 60], the sponge style of TUSC7
regulation toward to miR-146 released the controlling
of NUMB expression in PC9ER and HCC827ER cells,
which manipulated the DICER and cMYC cascade inner
cytoplasm [43, 46, 61, 62]. The absence of either cMYC
or DICER1 will lead to TUSC7 and miR-146 decreasing
respectively, formed the closed circle to maintain the new
balance.
To be concluded, the lncRNA of TUSC7 affected the
cancer progression and stem cells renewal, and TUSC7
suppression of Notch signaling determines the Erlotinib treatment response. PC9ER and HCC827ER cells
harbors much more stem-like groups, which dominated in therapy response, and their resistance could be

(See figure on next page.)
Fig. 4 m6A status was associated with TUSC7 inhibition and snail relating miR-146a overexpression. A M6A levels of RNAs from resistant cells were
statistically more abundant than sensitive original cells. METTL3 affected the miR-146a level (B), and YTHDF2 affected TUSC7 level (C). D-E The
results were all confirmed by using the lentiviral based METTL3/YTHDF2 knock-down systems. F-G Dysregulated METTL3 and YTHDF2 affected
the m6A, and then determined different EMT and stemness feature in resistant PC9ER cells and HCC827ER cells. H-I METTL3 inhibition decreased
m6A at Snai1. J Snai1 inhibition failed to activate the miR-146a promoter activity. K The m6A at TUSC7 level increased in resistant cells, and the
recognition of TUSC7 m6A peak by YTHDF2 degraded and downregulated the TUSC7 expression. L The Me-RIP assay confirmed that the high
abundance of m6A modification in cells with YTHDF2 inhibition

Li et al. J Exp Clin Cancer Res

(2021) 40:325

Fig. 4 (See legend on previous page.)
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Fig. 5 TUSC7 sensitized Erlotinib treatment and formed feedback loop with miR-146/Notch signaling cascade. A Notch signaling inhibition
resulted in cMYC promoter activity decreasing, and TUSC7 inhibition strongly increased the activity. B Inhibition of TUSC7 increased miR-146a
expression, and then stimulated the DICER1 activity. C The scheme image represented the cMYC promoter detection modes. D Western blotting
confirmed that in PC9ER and HCC827ER cells, miR-146 and TUSC7 acted the opposite way to promote the DICER1/CCND1 expression. E TUSC7 and
miR-146a was sustained by cMYC (Left) and DICER1 (Right) respectively. F The regulative signaling pathways were drafted and illustrated for detailed
exhibition. G In vivo study confirmed the effective inhibition of TUSC7 exhibited on tumor growth, and the Notch signaling inactivation by using
FLI-06 also suppressed the in vivo tumor expansion

reversed by Notch signaling inactivation. Interestingly
and importantly, the intrinsic miR-146 and TUSC7 levels are monitored and sustained by m6A effectors, and
disturbing the miR-146 and TUSC7 expression patterns
will push themselves to form the circling loop to sustain

the new homeostasis. Further in clinics, the combined
using of TKIs and Notch specific inhibitory non-coding
RNAs will pave the way for yielding the susceptibility to
targeted therapy in lung cancer.
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Additional file 1: Supplemental Figure 1. The sensitivity of Erlotinib in
treating Lung adenocarcinoma harboring mutant EGFR. The sensitivity
analysis was carried with using shared data of Genomics of Drug Sensitiv‑
ity in Cancer at the SANGER site. A. The Erlotinib sensitivity referring to
lung cancer samples of PAN data were rankly exhibited. B. The Erlotinib
sensitivity referring to lung adenocarcinoma samples were rankly exhib‑
ited. Both PC9 (C) and HCC827 (D) were sensitive to Erlotinib treatment
with concentration much lower than IC50. E. EGFR mutant lung cancer
cells are very sensitive to Erlotinib treatment, comparing to that of lung
cancer cells with wild type EGFR.
Additional file 2: Supplemental Figure 2. Signatures of the Erlotinib
resistant lung adenocarcinoma cells. A. Erlotinib decreased the Notch1
mRNA level in both PC9 and HCC827 cells. B. Erlotinib decreased the
Notch2 mRNA level in both PC9 and HCC827 cells. C. Erlotinib increased
the TUSC7 expression level significantly in both PC9 and HCC827 cells. D.
Addition of Erlotinib did not change the EGFR expression level in both
PC9 and HCC827 cells. E. Erlotinib decreased the Notch signaling factors
in PC9 and HCC827 cells. F. The newly established PC9ER and HCC827ER
were analyzed for lncRNAs expression patterns, and the primarily results
were showed in Heatmap. G. The differentially expressed LncRNAs
between Erlotinib resistant cells and sensitive cells were categorized by
using GO analysis, and TUSC7 was supposed to be inhibited in PC9ER
and HCC827ER cells. Real-time PCR further confirmed the suppression of
TUSC7 in PC9ER (H) and HCC827ER (I) cells.
Additional file 3: Supplemental Figure 3. Establishing the Erlotinib
resistant cells. A. Osimertinib was dissolved in dimethyl sulfoxide (DMSO),
and a total of 1 × 106 cells/ml of H1975 cells were seeded in a 6-wells plate
and incubated in RPMI-1640 medium containing Osimertinib. The initial
concentrations of Osimertinib were started with a concentration equal to
the half-maximal inhibitory concentration of H1975 cells. After a cycle of
Osimertinib treatment, only a small percentage of cells remained. Once
cells had resumed normal growth and returned to 80% confluence under
the light microscope, the next cycle began. The drug concentration was
gradually increased for the next cycle until cells could survive with 10 μM
Osimertinib. After 6 months, the H1975OR cells were successfully estab‑
lished and were then harvested for RNAs analysis. B. The images of gene
probes detection were exhibited for illustration.
Additional file 4: Supplemental Figure 4. TUSC7 re-sensitized the
resistant PC9ER cells and HCC827ER cells through Notch signaling inhibi‑
tion. A-B. All lung cancer cells responded to Notch signaling inhibitors
greatly, and the much-lowered concentration of Notch signaling inhibitor
sensitized both PC9ER and HCC827ER cells to Erlotinib treatment. TUSC7
stimulated the suppressive functions of Erlotinib in both PC9ER (C) and
HCC827ER cells (D). E. Differences of the proliferation inhibition ratios
between TUSC7 alone and the combination of TUSC7 and FLI-06 was
insignificant. F-G. Supplemented images.
Additional file 5: Supplemental Figure 5. Blotting results to prove that
TUSC7 functioned through Notch signaling inhibition in resistant PC9ER
cells and HCC827ER cells. The combined TUSC7 and Notch signaling
inhibitor decreased the stem cells associated signatures, and decreased
the EMT markers in PC9ER cells (A) and HCC827ER cells (B), but the inhibi‑
tory result was similar to that of using either TUSC7 or Notch signaling
inhibitor alone.
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